Citations

Clear

1279 citation(s) found for "Taylor, A".

Abstract PR004: BTK A428D is a recurrent pan-resistance mutation to BTK degraders in clinical trials
Sievers, Quinlan, Lu, Hao, Cool, Allison , Grajewski, Stefan, Kong, Tim , Noviski, Mark, Mukerji, Ratul , Iuliano, James, Ye, Jordan , Rios, Mateo Sanchez Garcia de los, Bousquet, Hugo , Whelan, Sarah , Tan, May, Phelps, Christopher, Raman, Jahan, Notti, Ryan, Navarrete, Lizbeth Mendoza, Sekeres, Samantha, Lamkin, Eria, Bravo, Eduardo , Ewalt, Mark, Islam, Prioty , Mato, Anthony, Roeker, Lindsey, Taylor, Justin, Thompson, Meghan, Hansen, Gwenn, Abdel-Wahab, Omar, Sievers, Quinlan , Noviski, Mark , Mi, Xiaoli , Ficici, Emel , Iuliano, James N , Bousquet, Hugo, Notti, Ryan Q , Ewalt, Mark D. , Mato, Anthony R. , Roeker, Lindsey E. , Hansen, Gwenn M , Abdel‐Wahab, Omar

Mayo Clinic

Blood Cancer Discovery | June 24, 2026 | Volume: 7 | Issue: 3_Supplement | Pages: PR004-PR004

10.1158/2643-3249.lymphoma26-pr004 Get It

Abstract Early-phase clinical trials of BTK degraders in relapsed/refractory CLL have shown response rates of over 80%, including in patients with BTK mutations that confer resistance to conventional BTK inhibitors (BTKi). The molecular basis of resistance to BTK degraders is unknown and, given the promise of this class of drugs, would hold implications for therapy sequencing and the design of next-generation BTK degraders. To this end we identified five patients at Memorial Sloan Kettering who developed progressive disease while being treated on the phase 1 trials of zelebrudomide (NCT04830137, 4 patients) or bexobrutideg (NCT05131022, 1 patient). In two patients, one treated with zelebrudomide and the other with bexobrutideg, a pre-existing BTK A428D mutation had expanded at progression, rising from <1.5% at the start of treatment to >25%. In both cases, the increase in frequency of BTK A428D coincided with the loss of BTK degradation in peripheral blood B cells. No mutation in cereblon, the ligase utilized by these BTK degraders, was detected. To validate these clinical findings we generated wild-type and BTK A428D knock-in single-cell clones in TMD8 and HBL1 cells. BTK A428D conferred resistance to BTKi, including ibrutinib, acalabrutinib, zanubrutinib, and pirtobrutinib, as well as the clinical-stage BTK degraders zelebrudomide, bexobrutideg, BGB-16673, and AbbVie-1 (Compound 1, WO 2023183811). BTK A428D’s pan-resistance is unique compared to previously studied BTKi resistance mutations which remain susceptible to at least one BTKi and all clinical-stage BTK degraders tested. To understand how BTK A428D confers pan-resistance to BTKi and BTK degraders we conducted surface plasmon resonance studies which demonstrated that BTKi and all four clinical-stage BTK degraders tested are unable to bind BTK A428D. We next solved the crystal structure of apo BTK A428D to 1.8Å, which revealed that the mutant aspartate, which is larger and negatively charged compared to the wild-type alanine, sterically blocks BTKi and degraders from accessing residues in the hinge region of the kinase that are required for drug binding. We next asked why BTK A428D, despite conferring pan-resistance, has only been detected in 1.1% of patients treated with BTK inhibitors. Intriguingly, we noted that in one of our index patients, the frequency of BTK A428D declined and became undetectable after the withdrawal of zelebrudomide, suggesting a fitness defect. To assess this hypothesis, we compared the proliferation rates of five TMD8 wild-type and five BTK A428D single-cell clones; the BTK A428D clones grew more slowly and were consistently outcompeted in mixing studies. In summary, low-frequency BTK A428D mutations can expand under the selection pressure of BTK degraders and confer clinical resistance by preventing drug binding. The mutation, however, is outcompeted in the absence of BTK-targeted therapies. These findings provide rationale for the investigation of combination therapies and the development of next-generation BTK degraders capable of circumventing BTK A428D. Citation Format: Quinlan Sievers, Hao Lu, Allison Cool, Stefan Grajewski, Tim Kong, Mark Noviski, Xiaoli Mi, Emel Ficici, Ratul Mukerji, James Iuliano, Jordan Ye, Mateo Sanchez Garcia de los Rios, Hugo Bousquet, Sarah Whelan, May Tan, Christopher Phelps, Jahan Raman, Ryan Notti, Lizbeth Mendoza Navarrete, Samantha Sekeres, Eria Lamkin, Eduardo Bravo, Mark Ewalt, Prioty Islam, Anthony Mato, Lindsey Roeker, Justin Taylor, Meghan Thompson, Gwenn Hansen, Omar Abdel-Wahab. BTK A428D is a recurrent pan-resistance mutation to BTK degraders in clinical trials [abstract]. In: Proceedings of the Fifth AACR International Meeting on Advances in Malignant Lymphoma: From Discovery to Clinical Impact; 2026 Jun 24-27; Philadelphia, PA. Philadelphia (PA): AACR; Blood Cancer Discov 2026;7(3_Suppl):Abstract nr PR004.
Clinical Associations of Cerebrospinal Fluid TMEM106B in Familial and Sporadic Frontotemporal Dementia
Olzinski, Molly, Downer, Joshua, Rajbanshi, Binita, Li, Jingyao, Loureiro, Joseph, Heuer, Hilary, Ljubenkov, Peter, Vandevrede, Lawren, Staffaroni, Adam, Lario‐Lago, Argentina, Leichter, Dana, Wolf, Amy, Wise, Amy, Sanderson-Cimino, Mark, Barragan, Eden, Spina, S, Grinberg, Lea T., Seeley, William W., Casaletto, Kaitlin B., Kramer, Joel, Ramos, Eilana, Geschwind, Daniel, Cook, Casey, Petrucelli, L, Forsberg, Leah K., Gendron, Tania, Boeve, Bradley F., Rademakers, Rosa, Rosen, Howard J., Saloner, Rowan, Boxer, Adam L., Rojas, Julio C., Abdullah, M. Samy, Apostolova, Liana, Appleby, Brian, Bayram, Ece, Hp, Botha, Bozoki, Andrea, Brushaber, Danielle, Clark, David, Considine, Ciaran M., Darby, R. Ryan, Day, Gregory S., Dickerson, Bradford C., Dickson, Dennis, Domoto-Reilly, Kimiko, Dwosh, Emily, Faber, Kelley M., Fields, Julie A. , Fong, Jamie C., Foroud, Tatiana, Galasko, Douglas R., Gavrilova, Ralitza, Ghoshal, Nupur , Goldman, Jill, Graff-Radford, Jonathan, Graff-Radford, Neill, Grant, Ian M., Cn, Hales, Honig, Lawrence S., Gd, Hsiung, Huey, Edward D, Irwin, David, Jones, David T., Kantarci, Kejal, Knopman, David, Kolander, Tyler , Kornak, J M, Kremers, W., Kwan, Justin , Lapid, Maria, Lee, Suzee, Litvan, Irene, Lucente, Diane, Mackenzie, Ian R., Masdeu, J C, Massimo, Lauren, McGinnis, Scott, McMillan, Corey T., Mendez, Mario F., Mester, Carly, Miyagawa, Toji , Molden, Joie, Onyike, Chiadi, Pantelyat, Alexander, Pascual, Belen, Paulson, Henry, Ramanan, Vijay, Rankin, Katherine P., Rascovsky, Katya, Rhoads, Kristoffer , Savica, Rodolfo, Snyder, Allison, Sullivan, A. Campbell, Syrjanen, Jeremy, Tartaglia, M, Taylor, Jack, Tipton, P E, WEINTRAUB, S, Wint, Dylan, Wong, Bonnie, Yokoyama, Jennifer, Paulson, Henry L. , Barmada, Sami J. , Paulson, Henry L , Barmada, Sami , Cobigo, Yann , Worringer, Kathleen A. , Heuer, Hilary W. , VandeVrede, Lawren , Staffaroni, Adam M. , Wolf, Amy , Wise, Amy B. , Sanderson‐Cimino, Mark , Barragan, Eden V. , Grinberg, Lea T. , Seeley, William W. , Casaletto, Kaitlin B. , Kramer, Joel, Ramos, Eliana Marisa , Geschwind, Daniel H. , Forsberg, Leah K. , Gendron, Tania F. , Boeve, Bradley F. , Perneel, Jolien , Rademakers, Rosa , Rosen, Howard J. , Saloner, Rowan , Boxer, Adam L. , Rojas, Julio C. , Appleby, Brian S. , Barmada, Sami, Bayram, Ece , Botha, Hugo, Bozoki, Andrea C , Brushaber, Danielle , Clark, David, Considine, Ciaran , Dickerson, Bradford Clark , Dickson, Dennis, Domoto‐Reilly, Kimiko , Dwosh, Emily , Foroud, Tatiana, Graff‐Radford, Jonathan , Graff-Radford, Neill, Hales, Chadwick M., Honig, Lawrence S. , Hsiung, Ging-Yuek R., Huey, Edward D. , Jones, David T., Kantarci, Kejal , Kornak, John , Kremers, Walter, Kwan, Justin, Léger, Gabriel C. , Litvan, Irene , Lucente, Diane , Mackenzie, Ian R. , Massimo, Lauren , McGinnis, Scott, McMillan, Corey T. , Mendez, Mario F. , Mester, Carly , Pascual, Belén , Ramanan, Vijay, Rankin, Katherine P. , Roberson, Erik D. , Savica, Rodolfo , Snyder, Allison , Sullivan, A. Campbell , Syrjanen, Jeremy A. , Taylor, Jack C. , Tipton, Philip W., Vandebergh, Marijne , Weıntraub, Sandra , Wint, Dylan

Mayo Clinic

JAMA Neurology | June 22, 2026 | Volume: 83 | Issue: 8 | Pages: 778

10.1001/jamaneurol.2026.1927 | PMID 42329632 Get It

Importance TMEM106B is a frontotemporal lobar degeneration (FTLD) genetic susceptibility factor, and TMEM106B protein aggregates are a feature of aging and neurodegeneration. Whether TMEM106B protein levels are associated with clinical features is unknown. Objective To investigate the clinical associations of cerebrospinal fluid (CSF) TMEM106B in FTLD. Design, Setting, and Participants This cross-sectional study was conducted in 2 independent frontotemporal dementia (FTD) cohorts (recruitment from April 2009 through July 2023, with analyses from January 2025 through April 2026), with a 2-year follow up. This multicenter clinical study integrated clinical, genetic, biomarker, and neuroimaging data. Individuals were recruited through the University of California, San Francisco (n = 3733), or ALLFTD (n = 2343). Participants with available CSF were included. A discovery cohort (n = 271) included participants with sporadic neuropathology-confirmed FTLD; presymptomatic or symptomatic carriers of pathogenic variants in C9orf72 , GRN , or MAPT ; or controls. An independent validation cohort (n = 383) included participants with clinically diagnosed sporadic FTD, Alzheimer disease (AD), and controls. Exposures CSF samples for TMEM106B quantification with aptamer proteomics (SomaScan version 3.0 [discovery cohort] and SomaScan version 4.1 [validation cohort]). Main Outcomes and Measures Parametric tests compared the primary outcome, CSF TMEM106B, by disease severity, TMEM106B rs1990622 genotype, sex, clinical syndrome, pathological diagnosis, and pathogenic variant and determined associations with brain volume. Results In the discovery (n = 271; 136 women [51%]; median [IQR] age, 59 [38-80] years) and validation (n = 383; 183 women [48%]; median [IQR] age, 64 [50-78] years) cohorts, lower CSF TMEM106B was associated with more severe disease (β, −0.15; 95% CI, −0.24 to −0.04; P = .003), lower frontotemporal brain volumes (β, 0.42; 95% CI, 0.24-0.61; P < .001), and faster clinical progression (β, −2.21; 95% CI, −3.70 to −0.72; P = .001). Associations of TMEM106B with clinical disease severity were independent of those with neurofilament light chain. TMEM106B levels were influenced by TMEM106B rs1990622 genotype, where individuals with the protective G/G genotype had lower levels than the risk A/A genotype. CSF TMEM106B levels did not differentiate between FTLD subtypes or between FTLD and AD. Conclusions and Relevance Per the results of this cross-sectional study, TMEM106B is detectable in CSF and levels reflect disease severity in sporadic and genetic FTLD and AD, but levels are also influenced by the TMEM106B rs1990622 genotype. CSF TMEM106B could support further studies to understand the mechanisms of disease and develop clinical tools in FTLD and other neurodegenerative diseases.
Real‐world, multi‐omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS)
Sauta, Elisabetta, Lanino, Luca, Bewersdorf, Jan P, Kewan, Tariq, Ali, Najla H. Al, Fenaux, Pierre, Platzbecker, Uwe, Santini, Valeria, Brunner, Andrew M., Kuykendall, Andrew T., Bennett, John M. , Buckstein, Rena, Bejar, Rafael, Carraway, Hetty E., DeZern, Amy E., Hasserjian, R., Loghavi, Sanam, Odenike, Olatoyosi, Padron, Eric , Patnaik, Mrinal M., Stahl, Maximilian, Sekeres, M., Steensma, David P., Savona, Michael R., Taylor, Justin, Xu, Mina L., Sallman, David A., Nimer, Stephen D. , Hourigan, Christopher S., Wei, Andrew H., Riva, Elena , Ventura, Denise, Pinocchio, Nicole, Buizza, Alessandro , Russo, Antonio, D'Amico, Saverio, Delleani, Mattia , Travaglino, Erica , Tentori, Cristina A., Ferrari, Ivan, Crespi, Alessandra, Figini, Giulia , Matteo, Maria Di, Milanesi, Chiara, Castellani, Gastone, Borate, Uma M., Gore, Steven D., Kim, Tae K., Loosdrecht, Arjan A. van de , Daver, N., Wang, Sa A. , Foucar, Kathryn, Iastrebner, Marcelo, Miyazaki, Yasushi, Al‐Kali, Aref, Mittelmann, Moshe, Cluzeau, Thomas , Ades, Lionel, Germing, Ulrich, Garcia‐Manero, Guillermo, Kordasti, Shahram, Haferlach, Torsten, Zeidan, Amer M., consortia, An international study on behalf of GenoMed4all, Synthema, and icMDS, Zeidan, Amer M. , Buizza, Alessandro , Ficara, Francesca , Efficace, Fabio , Diez-Campelo, Maria , Orfao, Alberto , Wang, Sa A , Cluzeau, Thomas , Komrokji, Rami S , Della Porta, Matteo Giovanni , Zeidan, Amer M , Maggioni, Giulia , Todisco, Gabriele , Sauta, Elisabetta , Lanino, Luca , Ball, Somedeb , Bewersdorf, Jan Philipp , Fenaux, Pierre , Platzbecker, Uwe , Santini, Valeria , Xie, Zhuoer , Brunner, Andrew M. , Kuykendall, Andrew , Buckstein, Rena , Bejar, Rafael , Carraway, Hetty E. , Dezern, Amy Elizabeth , Griffiths, Elizabeth A. , Halene, Stephanie , Hasserjian, Robert P. , List, Alan F. , Loghavi, Sanam , Odenike, Olatoyosi , Patnaik, Mrinal M. , Roboz, Gail J. , Sekeres, Mikkael A. , Steensma, David P. , Savona, Michael R. , Sallman, David A. , Hourigan, Christopher S. , Wei, Andrew H. , Campagna, Alessia , Ubezio, Marta , Ventura, Denise , Pinocchio, Nicole , Zampini, Matteo , Russo, Antonio , Pesce, Francesco , D'Amico, Saverio , Asti, Gianluca , Tentori, Cristina Astrid , Ferrari, Ivan , Matteo, Maria Di, Brindisi, Matteo , Manes, Nicla , Crisafulli, Laura , Ficara, Francesca , Castellani, Gastone , Borate, Uma , Efficace, Fabio , Gore, Steven D. , Díez‐Campelo, María , Rozman, Marı́a , Órfão, Alberto , Foucar, Kathryn , Iastrebner, Marcelo , Scheinberg, Phillip , Miyazaki, Yasushi , Madanat, Yazan F. , Al‐Kali, Aref , Mittelman, Moshe , Adès, Lionel , Germing, Ulrich , Garcia‐Manero, Guillermo , Kordasti, Shahram , Haferlach, Torsten , Komrokji, Rami S.

Mayo Clinic

HemaSphere | June 22, 2026 | Volume: 10 | Issue: 6 | Pages: No page available

10.1002/hem3.70406 | PMID 42339339 Get It

Abstract Myelodysplastic syndromes (MDS) are clinically and biologically diverse disorders, emphasizing the need for personalized treatment approaches. The International Working Group for Prognostication of MDS (IWG_PM) recently introduced a molecular classification, referred to as the MDS taxonomy, that categorizes patients into 16 subgroups based on 21 gene mutations, 6 cytogenetic abnormalities, and loss of heterozygosity (LOH) at TP53 and TET2 loci. This study sought to validate and enhance the clinical relevance of the MDS taxonomy by analyzing a large retrospective cohort ( n = 5136) and transcriptomic data from a prospective cohort ( n = 477). The taxonomy successfully identified subgroups with distinct clinical characteristics and disease progression patterns. However, incorporating gene interactions from taxonomy subgroups did not improve the prognostic performance of the Molecular International Prognostic Scoring System (IPSS‐M). We further assessed whether the taxonomy could guide management in patients receiving disease‐modifying therapies. Except for the “ TP53 ‐complex” subgroup, taxonomy classifications were not predictive of hypomethylating agent response or transplant outcomes. Nonetheless, they correlated with overall survival, suggesting that while both IPSS‐M and the taxonomy capture disease biology, other non‐genetic factors may influence treatment response. RNA sequencing confirmed the biological distinctiveness of the taxonomy groups. Transcriptomic profiling of CD34+ bone marrow cells revealed unique, homogeneous gene expression patterns, particularly within the AML‐like, bi TET2 , SF3B1 , and TP53 ‐complex subgroups. Further integration of multi‐omics data may refine MDS classification, improving clinical decision‐making and guiding the development of targeted therapies.
Artificial Intelligence Models for Classifying Wrist Ligament Injuries Using Synthetically-Generated Joint Proximity Maps from Finite Element Models
Chen, Hsuan-Yu, Camp, Jon, Thoreson, Andrew R. , Leng, Shuai , Holmes, David R. , Kakar, Sanjeev , An, Kai‐Nan , Zhao, Kristin D. , Andreassen, Thor E. , Yu Chen, Hsuan, Trentadue, Taylor P , Thoreson, Andrew R , Leng, Shuai , Holmes, David R , Kakar, Sanjeev , An, Kai-Nan , Trentadue, Taylor P , Andreassen, Thor E , Camp, Jon J. , Trentadue, Taylor P.

Mayo Clinic

No container title available | June 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.17.733030 | PMID 42367846 Get It

Abstract Background/Purpose Diagnosing wrist ligament injuries is challenging; early detection and treatment are important to prevent osteoarthritis progression. Interosseous proximity maps, a proxy measure for joint space, can be generated from volumetric imaging data and may provide important information about wrist health. Artificial intelligence (AI) could enhance accuracy of noninvasive diagnosis based on imaging-derived metrics. This work demonstrates feasibility of AI training using synthetic proximity map data generated from finite element models (FEMs). Methods Personalized wrist FEMs for two asymptomatic participants were created from four-dimensional computed tomography-derived anatomic and kinematic data. Monte Carlo sampling varied 22 ligament material properties and simulated 7,500 unique injury scenarios generating 9,000,000 labeled red, green, and blue (RGB) images of interosseous proximity vector fields from FEM-derived motions. Images were associated with 17 descriptive metrics, including gross wrist angles and bone surface pairs, and used to develop mixed-input convolutional neural networks (CNNs). Model performance was evaluated for identifying specific ligament injuries. Results Average area under receiver operating characteristic curve (AUROC) for CNNs was 0.757 across all injury types and kinematics. In a subset with clinically-relevant functional angles, the average AUROC was 0.824. Best-performing individual ligament AUROCs ranged from 0.807 to 0.999. Sensitivities and specificities exceeded 0.99 for some ligament injury simulations under specific wrist angles and bone surface pairs. Conclusion This study demonstrates the feasibility of using synthetic data from FEMs to train AI models for classifying wrist ligament injuries. Proximity-based RGB images may be a relevant biomarker of ligamentous injury.
Emerging directions in tauopathy research
Wildsmith, Kristin R., Alladi, Suvarna, Bertucci, Taylor, Bowles, Kathryn R. , Boxer, Adam, Brummet, Jennifer, DeVos, Sarah L., Diaz, Kristophe , Duff, Karen, Duran‐Aniotz, Claudia, Farrell, Kurt, Fontana, Igor C., Franzmeier, Nicolai, Frost, Bess, Petrucelli, Leonard, Rexach, Jessica, Reyderman, Larisa, Rommel, Amy, Bohórquez, Sandra M. Sanabria, Schöll, Michael, Schneider, Anja, Silva, Rohan de , Snyder, Heather M. , VandeVrede, Lawren, Varga, Andrew W, Vogel, Jacob W., Yeh, Felix L. , Yoo, Andrew S., Carrillo, Maria C., Duff, Karen , Bertucci, Taylor , Mahinrad, Simin , Buée, Luc , Alladi, Suvarna , Boche, Delphine , DeVos, Sarah L. , Dreyer, Anna J. , Duran‐Aniotz, Claudia , Durrant, Claire S. , Farrell, Kurt , Fontana, Igor C. , Franzmeier, Nicolai , Frost, Bess , Horie, Kanta , Kaňovský, Petr , Kao, Aimee W. , Mahinrad, Simin , Malpetti, Maura , Morris, Huw R. , Palleis, Carla , Petrucelli, Leonard , Rexach, Jessica E. , Reyderman, Larisa, Rowe, James B. , Bohórquez, Sandra Sanabria , Sato, Chihiro , Schneider, Anja , VandeVrede, Lawren , Varga, Andrew W. , Vogel, Jacob W. , Yoo, Andrew S.J. , Carrillo, María C.

Mayo Clinic

Alzheimer's & Dementia | June 22, 2026 | Volume: 22 | Issue: 6 | Pages: No page available

10.1002/alz.71431 | PMID 42324487 Get It

Abstract The Tau Global Conference 2025, hosted by the Alzheimer's Association, CurePSP, and the Rainwater Charitable Foundation, convened international experts from academia, industry, government, and philanthropy to explore advances and challenges in tauopathy research. The meeting highlighted progress across tau biology, including emerging models of tau regulation, degradation, and propagation; advances in biomarker development for the diagnosis and staging of tauopathies; and evolving therapeutic strategies targeting diverse aspects of tau pathophysiology. Discussions also emphasized the importance of cross‐sector collaboration, and global initiatives to address disparities in tau research. This report synthesizes key insights from the conference and underscores the critical role of interdisciplinary, biomarker‐driven, and globally inclusive approaches in accelerating the translation of tau research into effective clinical applications.
Equations in Context: Estimating and Interpreting Cardiorespiratory Fitness
Carlisle, Ashley E., Shapiro, Brian P. , Tayon, Kevin G. , Taylor, Bryan J., Dineen, Elizabeth H.

Mayo Clinic

ACSM'S Health & Fitness Journal | June 18, 2026 | Volume: 30 | Issue: 4 | Pages: 24-30

10.1249/fit.0000000000001172 Get It

Apply It! By reading this article, you will: • Understand how commonly used cardiorespiratory fitness prediction equations can misclassify fitness in both high-performance and clinical populations. • Learn how common prediction equations were developed and why the population of prediction equation studies matters when interpreting estimated cardiorespiratory fitness and percent-predicted values. • Recognize how to critically assess the suitability of a given cardiorespiratory fitness equation based on your client’s or patient’s characteristics.
Development of a Core Outcome Domain Set for Facial Aging
Dirr, McKenzie A. , Ahmed, Areeba, Schlessinger, Daniel I., Lazaro-Camp, Vanessa, Smith, SJ, Gullapalli, Thanvi, Dragovic, Doroteja, Chang, Joycie, Zhang, Elizabeth, Alam, Murad, Group, Facial Aging Core Outcome Domain Set Study, Anvery, Noor , Kang, Bianca Y. , Wong, Clarissa, Iyengar, Sanjana, Yanes, Arianna F. , Cotseones, Jill, Ashchyan, Hovik J. , Patel, P. M., Sheikh, Umar A., Franklin, Matthew , Hanna, Courtney, Chiren, Sarah G., Schmitt, J, Furlan, Karina C., Alexiades, Macrene, Alhusayen, Raed, Alster, Tina S. , Beer, Kenneth, Bertucci, Vince , Bloom, Jason D. , Briceño, César A., Bucay, Vivian, Butterwick, Kimberly J., Hugues, Cartier, Casabona, Gabriela, Connolly, Karen , Cox, Sue Ellen , Darmanescu, Monica, Boulle, Koenraad De , Desai, Shraddha, Donofrio, Lisa, Dover, Jeffrey S., Draelos, Zoe, Eisen, Daniel B. , El-Domyati, Moetaz, El-Garem, Yehia, Fischer, John, Fitzgerald, Rebecca, GALADARI, Hassan, Gladstone, Hayes B., Goldman, Mitchel P., Goodman, Greg J., Hanke, C. William , Humphrey, Shannon, Ibrahim, Sherrif F., Jagdeo, Jared, Karen, Julie, Kauvar, Arielle, Ag, Kibbi, KIM, JENNY, Lacerda, D T D, Lask, G, Lopez, Grace M., Lupo, Mary P. , Mariwalla, Kavita , Matarasso, Seth, Mekokishvili, L, Narins, Rhoda S., Ogilvie, P, Orringer, Jeffrey S. , Osaki, Tammy H. , Ozog, David, Pacheco, Theresa, Polder, Kristel, Rossi, Anthony M, Sadick, Neil, Saedi, Nazanin, Schlessinger, Joel, Sharad, Jaishree , Shenoy, SuchitraM, Sinclair, Rd, Solish, Nowell, Piansay‐Soriano, Miriam Emily , Sulyman, Omotara , Szeimies, Rolf‐Markus , Tanzi, Elizabeth L., Taub, Amy Forman , Taylor, Mark B., Thomas, J. Regan, Torezan, Luis, Tosti, Antonella, Touma, Dany, Almeida, Ada Regina Trindade de , Vedamurthy, Maya , Viana, Giovanni, Waldman, Abigail, Weinkle, Susan, Weiss, Robert, Poon, Emily, Cartee, Todd V. , Sobanko, Joseph F. , Eisen, Daniel B. , Ahmed, Areeba , Schlessinger, Daniel Isaac , Lazaro-Camp, Vanessa J, Christensen, Rachel E. , Ibrahim, Sarah A. , Cotseones, J.K., Umar, Sheikh Ahmad , Furlan, Karina Colossi , Alexiades, Macrene , Alhusayen, Raed , Beer, Kenneth Robert, Briceño, César Augusto , Bucay, Vivian , Casabona, Gabriela , Cotofana, Sebastian , Desai, Shraddha , Dover, Jeffrey S. , Draelos, Zoe Diana , Eisen, Daniel B., El-Domyati, Moetaz M. , El-Garem, Yehia, Fitzgerald, Rebecca, Friedmann, Daniel P. , Galadari, Hassan , Gladstone, Hayes B., Goldman, Mitchel P. , Goodman, Greg , Green, Jeremy B. , Halachmi, Shlomit , Humphrey, Shannon , Jagdeo, Jared R. , Jiang, Shang I. Brian , Kauvar, Arielle N.B. , Kibbi, Abdul‐Ghani , Kim, John V. S., LASK, GARY P., Matarasso, Seth L., Narins, Rhoda S., Ogilvie, Patricia , Osaki, Tammy H. , Pacheco, Theresa , Polder, Kristel D., Saedi, Nazanin, Shenoy, Manjunath , Sinclair, Rod, Solish, Nowell , Torezan, Luís , Tosti, Antonellá , Waldman, Abigail , Weiss, Robert, Maher, Ian A. , Kirkham, Jamie J

Mayo Clinic

JAMA Dermatology | June 17, 2026 | Volume: 162 | Issue: 8 | Pages: 829

10.1001/jamadermatol.2026.1697 | PMID 42307924 Get It

Importance Currently, there are no standardized outcome domains or measures in clinical trials for facial aging. Heterogeneity in outcome domains and measurement instruments across clinical trials creates difficulty in directly comparing interventions, determining superior therapies, and developing high-quality meta-analyses. Objective To develop a core outcome set (COS) of essential domains to be reported in clinical trials evaluating the efficacy of interventions for facial aging. Evidence Review PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials, and CINAHL were searched from September 2005 to September 2015. An updated search of the same databases was performed from September 2015 to February 2026. Studies were included if (1) they were randomized clinical trial or controlled clinical trial in design, (2) they assessed the efficacy or safety of an intervention for facial aging, (3) they were published in English, and (4) they involved human participants. Complementary sources, including patient interviews, were used to capture further relevant outcomes. Two rounds of Delphi surveys, followed by consensus meetings, were used to identify outcome domains considered most important by both patient and physician stakeholders. Findings The final COS consists of 6 outcome domains: (1) overall convenience of treatment; (2) time to return to normal work and social activity; (3) overall assessment of focused area of treatment (at the point in time when treatment is expected to provide peak benefit); (4) duration of treatment effect; (5) severity of persistent local or systemic adverse events, including pigmentary change, skin texture change, delayed healing, scarring, and serious adverse events; and (6) patient satisfaction with treatment. Conclusions and Relevance The 6 outcome domains identified through a Delphi consensus are recommended for reporting in future facial aging trials to ensure that outcomes that matter most to patients and clinicians are measured and that results are comparable across interventions.
Remote, self‐administered, smartphone cognitive testing in a registry‐based cohort: Feasibility, reliability, and validity findings
Dhanam, Sreya , Taylor, Jack C. , Fregly, Ray, Kwang, Winnie, Wise, Amy B. , Heuer, Hilary W. , Forsberg, Leah K. , Kramer, Joel H. , Rosen, Howard J., Mackin, R. Scott , Weiner, Michael W., Nosheny, Rachel L. , Boxer, Adam L., Staffaroni, Adam M. , Registry, and the Brain Health, Staffaroni, Adam M , Sanderson‐Cimino, Mark , Paolillo, Emily W. , Maruff, Paul , Boeve, Bradley F. , Boxer, Adam L. , Registry, and the Brain Health

Mayo Clinic

Alzheimer's & Dementia | June 11, 2026 | Volume: 22 | Issue: 6 | Pages: No page available

10.1002/alz.71580 | PMID 42273832 Get It

Abstract BACKGROUND Remote, smartphone‐based cognitive testing may improve access to cognitive assessments for Alzheimer's disease and related dementias. We evaluated the feasibility, reliability, and validity of unsupervised smartphone‐based cognitive tests in a registry‐based cohort. METHODS Adults without a record of cognitive impairment ( N = 1815; ages 18–92) were recruited from the University of California, San Francisco (UCSF) Brain Health Registry to complete three unsupervised smartphone cognitive testing sessions within 2 weeks. Reliability was assessed with correlations between sessions. Linear regression models tested associations of smartphone tasks with demographics, self‐ and informant‐rated cognitive concerns, and web‐based cognitive testing (Cogstate Brief Battery). RESULTS Adherence was high (82.2%) and usability favorable. Test–retest reliability was moderate to strong ( ρ ’s = 0.61–0.85, all p ’s < 0.001). Lower smartphone scores were associated with older age, lower education, cognitive concerns, and worse Cogstate performance. DISCUSSION Findings support the feasibility, reliability, and validity of remote digital assessments in adults without a record of cognitive impairment.
Stroke Characteristics, Management, and Outcomes in Patients with Non-bacterial Thrombotic Endocarditis: A Systematic Review (P7-4.019)
Aljabali, Ahmed, Taylor-Wedge, Hallie, Laffaye, T. , Al-Ahmad, Majd, Harahsheh, Ayham, Alamoush, Mohammad, Dweik, Khaled, Osundiji, Mayowa, Mbonde, Amir, Ocarroll, Cumara, Demaerschalk, Bart, Harahsheh, Ehab, Aljabali, Ahmed S. , Taylor, Hallie, Al-Ahmad, Majd Fayad Nimer, Mbonde, Amir A. , O’Carroll, Cumara B. , Demaerschalk, Bart M. , Harahsheh, Ehab

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215173 Get It

Cost of Care and Health Care Use among People Living with Multiple System Atrophy (P5-16.011)
Kymes, Steven, Ma, Xinshuo, Narayan, Veena, Wu, Xiyuan (Zoe), Taylor, Ken, Llonch, Montserrat Vera, Singer, Wolfgang , Vera‐Llonch, Montserrat

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217689 Get It